New York State Teachers Retirement System Reduces Stock Holdings in AbbVie Inc. $ABBV

New York State Teachers Retirement System decreased its position in AbbVie Inc. (NYSE:ABBV) by 2.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,441,063 shares of the company’s stock after selling 39,154 shares during the period. AbbVie comprises approximately 0.6% of New York State Teachers Retirement System’s portfolio, making the stock its 18th biggest holding. New York State Teachers Retirement System’s holdings in AbbVie were worth $329,268,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Chelsea Counsel Co. purchased a new position in AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter worth $31,000. WestEnd Advisors LLC lifted its position in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie during the third quarter worth $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 results: Revenue of $15.00B beat consensus and AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28, citing Skyrizi/Rinvoq strength. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Bank of America upgraded ABBV from Neutral to Buy and set a $234 price target, supporting upside vs. current levels.
• Positive Sentiment: Regulatory progress: AbbVie submitted FDA applications/label-expansion filings for Rinvoq (upadacitinib) in alopecia areata and other indications — potential sales tailwind if approved. AbbVie Submits Application to FDA for Upadacitinib
• Positive Sentiment: Pipeline/BD: AbbVie holds an option/warrant around Kestrel (KRAS program) that could lead to up to $1.45B in deal value and expands oncology exposure. AbbVie sinks talons into KRAS with right to buy Kestrel
• Positive Sentiment: Partner milestone: EvolveImmune nomination triggered an $18M milestone payment tied to its AbbVie collaboration — near‑term non‑core cash positive. EvolveImmune Therapeutics Announces Achievement
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) launched a May philanthropic campaign via Allē — positive PR but limited direct financial impact. Allergan Aesthetics Launches Philanthropic Effort
• Neutral Sentiment: Valuation commentary: Several analyst pieces are re‑assessing AbbVie after recent price weakness; useful for longer‑term investors but not an immediate catalyst. Assessing AbbVie Valuation
• Negative Sentiment: Analyst revisions: Erste Group trimmed FY2026/FY2027 EPS estimates modestly (small downward revisions) — a warning that some sell‑side forecasts are being re‑tuned.
• Negative Sentiment: Legacy declines: Humira and Imbruvica continue to contract; though newer immunology and neuroscience products offset much of the decline, legacy erosion remains a structural headwind. AbbVie tops quarterly expectations

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent research reports. Citigroup dropped their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Morgan Stanley increased their target price on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price on the stock. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $252.38.

AbbVie Price Performance

Shares of NYSE:ABBV traded up $9.92 during trading on Thursday, hitting $213.81. 2,486,347 shares of the company were exchanged, compared to its average volume of 7,138,852. The company has a market cap of $378.06 billion, a PE ratio of 90.79, a P/E/G ratio of 0.71 and a beta of 0.38. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The stock has a 50 day moving average of $214.80 and a 200 day moving average of $221.67.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, missing the consensus estimate of $3.01 by ($0.36). The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.